PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY

PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY

Show other versions (1)

The paper deals with the specific features of sunitinib tolerance in the treatment of metastatic renal-cell carcinoma. It considers in detail the drug’s side effects that are potential biomarkers of its efficacy.

Bibliographic Details
Main Authors: G. Yu. Kharkevich, L. V. Demidov
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Onkourologiâ
Subjects:
metastatic renal-cell carcinoma
sunitinib
side effects
markers of efficacy
Online Access:https://oncourology.abvpress.ru/oncur/article/view/91
id doaj-ec90128afec2401dad8ccb8388e6e4c8
record_format Article
spelling doaj-ec90128afec2401dad8ccb8388e6e4c82021-07-29T08:41:37ZrusABV-pressOnkourologiâ 1726-97761996-18122014-07-0192263410.17650/1726-9776-2013-9-2-26-34106PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACYG. Yu. Kharkevich0L. V. Demidov1N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowThe paper deals with the specific features of sunitinib tolerance in the treatment of metastatic renal-cell carcinoma. It considers in detail the drug’s side effects that are potential biomarkers of its efficacy.https://oncourology.abvpress.ru/oncur/article/view/91metastatic renal-cell carcinomasunitinibside effectsmarkers of efficacy
collection DOAJ
language Russian
format Article
sources DOAJ
author G. Yu. Kharkevich
L. V. Demidov
spellingShingle G. Yu. Kharkevich
L. V. Demidov
PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
Onkourologiâ
metastatic renal-cell carcinoma
sunitinib
side effects
markers of efficacy
author_facet G. Yu. Kharkevich
L. V. Demidov
author_sort G. Yu. Kharkevich
title PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
title_short PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
title_full PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
title_fullStr PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
title_full_unstemmed PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
title_sort practical recommendations for the use of sunitinib in the treatment of metastatic kidney cancer. adverse events – potential markers of its efficacy
publisher ABV-press
series Onkourologiâ
issn 1726-9776
1996-1812
publishDate 2014-07-01
description The paper deals with the specific features of sunitinib tolerance in the treatment of metastatic renal-cell carcinoma. It considers in detail the drug’s side effects that are potential biomarkers of its efficacy.
topic metastatic renal-cell carcinoma
sunitinib
side effects
markers of efficacy
url https://oncourology.abvpress.ru/oncur/article/view/91
work_keys_str_mv AT gyukharkevich practicalrecommendationsfortheuseofsunitinibinthetreatmentofmetastatickidneycanceradverseeventspotentialmarkersofitsefficacy
AT lvdemidov practicalrecommendationsfortheuseofsunitinibinthetreatmentofmetastatickidneycanceradverseeventspotentialmarkersofitsefficacy
_version_ 1721252742984368128

Similar Items